Oligonucleotide (Antisense oligonucleotide) · Acts on dystrophin (DMD) pre-mRNA (DMD) · developed by Sarepta Therapeutics
Vesleteplirsen (SRP-5051) is an intravenously administered oligonucleotide. It is studied in Duchenne muscular dystrophy, a disease of the DMD gene's dystrophin protein.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04004065 | Phase 2 | Duchenne Muscular Dystrophy | Terminated | SRPT |
| NCT03675126 | Phase 1/2 | Muscular Dystrophy, Duchenne | Terminated | SRPT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Duchenne Muscular DystrophyMuscular Dystrophy, Duchenne
Updated Nov 1, 2026. Something wrong or missing? Report it on the SRPT page.
See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SRPT catalysts and pipeline →